Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving

 
Thumbnail
View/Open
Author
Gay, Charlene
Published Version
https://doi.org/10.2217/pgs.15.28
Metadata
Show full item record
Citation
Wu, Ann Chen, Charlene Gay, Melisa D Rett, Natasha Stout, Scott T Weiss, and Anne L Fuhlbrigge. 2015. “Pharmacogenomic Test That Predicts Response to Inhaled Corticosteroids in Adults with Asthma Likely to Be Cost-Saving.” Pharmacogenomics 16 (6) (April): 591–600. doi:10.2217/pgs.15.28.
Abstract
Aim: To identify the clinical and economic circumstances under which a pharmacogenomic test that predicts response to inhaled corticosteroids might be a cost-effective option for individuals with asthma.

Materials & methods: We synthesized published data on clinical and economic outcomes to project 10-year costs, quality-adjusted life-years and cost–effectiveness of pharmacogenomic testing for inhaled corticosteroid response. We assumed the pharmacogenomic test cost was $500 with a sensitivity and specificity of 84 and 98%, respectively. These were varied in sensitivity analyses.

Results: Both strategies, pharmacogenomic testing for inhaled corticosteroid response and no testing conferred 7.1 quality-adjusted life-years. Compared with no testing, pharmacogenomic testing costs less.
Conclusion: Pharmacogenomic testing for asthma is cost-saving and noninferior in improving health.
Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545673/
Terms of Use
This article is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP
Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:27015682

Collections